Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by LOFARO222on Jan 11, 2021 11:09am

133 Views

Post# 32266844

Sponsored Post: Green Market Legacy

Nowadays, many companies are leaving a legacy in the market with the promising benefits of cannabis. Do you have a master plan for your health and your success?

Cannabis is a powerful holistic healing herb that impacting the body, mind, and spirit. It also utilizes the psychoactive effect to help identify the emotional and spiritual factors contributing to their pain. This approach has proven to be highly successful in providing long-term pain relief. Also, significantly reducing and eliminating opioids, addressing the causes of disease, and helping patients heal their lives.

It could be a good idea for you! Check my disclaimer on the profile and landing page.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading